Trials / Completed
CompletedNCT00718861
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
A 3-year, Multicenter, Double-blind, Randomized, Placebo-controlled Extension to CZOL446H2301E1 to Evaluate the Efficacy and Long Term Safety of 6 and 9 Years Zoledronic Acid Treatment of Postmenopausal Women With Osteoporosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Female
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | |
| DRUG | Zoledronic acid |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2008-07-21
- Last updated
- 2014-10-09
- Results posted
- 2013-12-30
Locations
57 sites across 18 countries: United States, Argentina, Australia, Belgium, Canada, Colombia, Finland, France, Germany, Hong Kong, Hungary, Italy, New Zealand, Norway, Poland, Sweden, Switzerland, Thailand
Source: ClinicalTrials.gov record NCT00718861. Inclusion in this directory is not an endorsement.